DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine Sulfate) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Prior to the use of this drug, patients and/or their parents/guardian should be advised of the possibility of untoward symptoms.

In general, adverse reactions are reversible and are related to dosage. The most common adverse reaction is hair loss; the most troublesome adverse reactions are neuromuscular in origin.

When single, weekly doses of the drug are employed, the adverse reactions of leukopenia, neuritic pain, and constipation occur but are usually of short duration (ie., less than 7 days). When the dosage is reduced, these reactions may lessen or disappear. The severity of such reactions seems to increase when the calculated amount of drug is given in divided doses. Other adverse reactions, such as hair loss, sensory loss, paresthesia, difficulty in walking, slapping gait, loss of deep–tendon reflexes, and muscle wasting, may persist for at least as long as therapy is continued. Generalized sensorimotor dysfunction may become progressively more severe with continued treatment. Although most such symptoms usually disappear by about the sixth week after discontinuance of treatment, some neuromuscular difficulties may persist for prolonged periods in some patients. Regrowth of hair may occur while maintenance therapy continues.

The following adverse reactions have been reported:

Hepatic veno-occlusive disease has been reported in patients receiving vincristine, particularly in pediatric patients, as part of standard combination chemotherapy regimens. Some of the patients had fatal outcomes; some who survived had undergone liver transplantation.

Hypersensitivity – Rare cases of allergic–type reactions, such as anaphylaxis, rash and edema, that are temporally related to vincristine therapy have been reported in patients receiving vincristine as a part of multidrug chemotherapy regimens.

Gastrointestinal – Constipation, abdominal cramps, weight loss, nausea, vomiting, oral ulceration, diarrhea, paralytic ileus, intestinal necrosis and/or perforation, and anorexia have occurred. Constipation may take the form of upper–colon impaction, and, on physical examination, the rectum may be empty. Colicky abdominal pain coupled with an empty rectum may mislead the physician. A flat film of the abdomen is useful in demonstrating this condition. All cases have responded to high enemas and laxatives. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine sulfate injection.

Paralytic ileus (which mimics the “surgical abdomen”) may occur, particularly in young pediatric patients. The ileus will reverse itself with temporary discontinuance of vincristine sulfate injection and with symptomatic care.

Genitourinary – Polyuria, dysuria, and urinary retention due to bladder atony have occurred. Other drugs known to cause urinary retention (particularly in the elderly) should, if possible, be discontinued for the first few days following administration of vincristine sulfate injection.

Cardiovascular – Hypertension and hypotension have occurred. Chemotherapy combinations that have included vincristine sulfate, when given to patients previously treated with mediastinal radiation, have been associated with coronary artery disease and myocardial infarction. Causality has not been established.

Neurologic – Frequently, there is a sequence to the development of neuromuscular side effects. Initially, only sensory impairment and paresthesia may be encountered. With continued treatment, neuritic pain and, later, motor difficulties may occur. There have been no reports of any agent that can reverse the neuromuscular manifestations that may accompany therapy with vincristine sulfate.

Loss of deep–tendon reflexes, foot drop, ataxia, and paralysis have been reported with continued administration. Cranial nerve manifestations, such as isolated paresis and/or paralysis of muscles controlled by cranial motor nerves including potentially life–threatening bilateral vocal cord paralysis, may occur in the absence of motor impairment elsewhere; extraocular and laryngeal muscles are those most commonly involved. Jaw pain, pharyngeal pain, parotid gland pain, bone pain, back pain, limb pain, and myalgias have been reported; pain in these areas may be severe. Convulsions, frequently with hypertension, have been reported in a few patients receiving vincristine sulfate. Several instances of convulsions followed by coma have been reported in pediatric patients. Transient cortical blindness and optic atrophy with blindness have been reported. Treatment with vinca alkaloids has resulted in both vestibular and auditory damage to the eighth cranial nerve. Manifestations include partial or total deafness which may be temporary or permanent, and difficulties with balance including dizziness, nystagmus, and vertigo. Particular caution is warranted when vincristine is used in combination with other agents known to be ototoxic such as the platinum–containing oncolytics.

Pulmonary – See Precautions.

Endocrine – Rare occurrences of a syndrome attributable to inappropriate antidiuretic hormone secretion have been observed in patients treated with vincristine sulfate. This syndrome is characterized by high urinary sodium excretion in the presence of hyponatremia; renal or adrenal disease, hypotension, dehydration, azotemia, and clinical edema are absent. With fluid deprivation, improvement occurs in the hyponatremia and in the renal loss of sodium.

Hematologic – Vincristine sulfate injection does not appear to have any constant or significant effect on platelets or red blood cells. Serious bone–marrow depression is usually not a major dose–limiting event. However, anemia, leukopenia, and thrombocytopenia have been reported. Thrombocytopenia, if present when therapy with vincristine sulfate injection is begun, may actually improve before the appearance of bone marrow remission.

Skin – Alopecia and rash have been reported.

Other – Fever and headache have occurred.



REPORTS OF SUSPECTED VINCRISTINE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Vincristine. The information is not vetted and should not be considered as verified clinical evidence.

Possible Vincristine side effects / adverse reactions in 82 year old female

Reported by a health professional (non-physician/pharmacist) from Turkey on 2011-10-03

Patient: 82 year old female

Reactions: Febrile Neutropenia

Adverse event resulted in: death

Suspect drug(s):
Cyclophosphamide
    Dosage: cycle 2

Rituximab

Doxorubicin Hydrochloride
    Dosage: cycle 1

Vincristine
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Indication: non-Hodgkin's Lymphoma

Prednisone
    Dosage: cycle 2
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 2

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: cycle 2

Prednisone

Doxorubicin Hydrochloride
    Dosage: cycle 2

Doxorubicin Hydrochloride
    Dosage: cycle 2

Doxorubicin Hydrochloride
    Dosage: cycle 1
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects / adverse reactions in 16 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-03

Patient: 16 year old male

Reactions: Tubulointerstitial Nephritis, Renal Tubular Acidosis

Suspect drug(s):
Ifosfamide
    Indication: Ewing's Sarcoma

Dactinomycin
    Indication: Ewing's Sarcoma

Vincristine
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma

Doxorubicin HCL
    Indication: Ewing's Sarcoma

Other drugs received by patient: Topiramate; Loperamide HCL; Potassium Bicarbonate; Fentanyl; Phosphate-Sandoz; Sodium Bicarbonate



Possible Vincristine side effects / adverse reactions in 35 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2011-10-03

Patient: 35 year old female

Reactions: Tumour Lysis Syndrome

Adverse event resulted in: death

Suspect drug(s):
Cyclophosphamide
    Dosage: 800 mg/m2, unk
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: 2 mg/body
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: 40 mg/m2, unk
    Indication: Burkitt's Lymphoma



See index of all Vincristine side effect reports >>

Drug label data at the top of this Page last updated: 2009-05-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014